Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Marie Skłodowska-Curie Action · Running

LYMON Laser-assisted sYnthesis of Magnetically mOtile plasmonic chiral Nanocatalysts

Coordinator
Universita Degli Studi Di Padova, Italy
Runs
1 April 2025 to 31 March 2027
Status
Running
EU funding
€189k
Total cost
—
Partners
2 organisations in 2 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101151748

What the project is doing

In the project's own words, from its summary on CORDIS.

Catalysis holds immense significance in chemical manufacturing, being a key player in developing sustainable industrial processes with limited energy & resource consumption. In pharmaceutical industry, catalysis is crucial for enabling mass production of affordable life-saving drugs. However, developing efficient catalysts for this sector poses a formidable challenge due to the inherent asymmetry of many biological processes.

This is particularly critical in producing anticancer drugs because their synthesis relies on intermediates or reactions whose asymmetric nature, known as chirality, withholds their massive production, limiting equal global access to best health treatments. An up-and-coming solution to address this dilemma is resorting to chiral plasmonic nanoparticles (NPs), as their outstanding optical rotation activity makes them well-suited for applications like polarization-sensitive photocatalysis, especially in the context of anticancer drug development.

However, unleashing its full potential hinges on imbuing these chiral NPs with unusual properties like magnetism, allowing safe removal from products & recyclability without generating chemical waste. To date, creating a plasmonic structure that seamlessly integrates chirality with magnetic motility remains largely underexplored. The LYMON project addresses this conundrum by expanding the repertoire of chiral nanocatalyst construction methods through a groundbreaking laser-based pathway.

This innovative approach, supported both experimentally & theoretically, promises to bring a new generation of highly specific magnetic chiroplasmonic nanocatalysts characterized by their ability to be reused multiple times. All of this permiting reducing wasteful side reactions & improving control over pharmaceutical production, especially for anticancer drugs. Moreover, it promises to expand the horizons of synthetic chemistry, paving the way for cutting-edge routes to produce highly efficient & selective molecules.

Topics

Who is involved

OrganisationCityCountryRole
Universita Degli Studi Di PadovaPadovaItalyCoordinator
Universidad De ExtremaduraBadajozSpainAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI